SEARCH

SEARCH BY CITATION

References

  • 1
    EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 30: 956961.
  • 2
    National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. HEPATOLOGY 2002; 36: S1S19.
  • 3
    Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004; 127: S294S302.
  • 4
    Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 10511055.
  • 5
    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174181.
  • 6
    Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. HEPATOLOGY 1998; 27: 13941402.
  • 7
    Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001; 48: 843848
  • 8
    Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141147.
  • 9
    Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101: 16121622.
  • 10
    Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al: Long-term clinical outcome of chronic hepatitis patients C who develop with sustained virological response to Interferon monotherapy. Gut 2004; 53: 15041508.
  • 11
    Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C, but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999; 30: 653659.
  • 12
    Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Ando M, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients whit sustained virologic response to interferon therapy. Liver Int 2004; 24: 603610.
  • 13
    Wright TL. Treatment of patients with hepatitis C and cirrhosis. HEPATOLOGY 2002; 36(Suppl. 1): S185S194.
  • 14
    Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593602.
  • 15
    Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SG. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 689698.
  • 16
    Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, et al. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol 1994; 20: 117121.
  • 17
    Kondo F, Ebara M, Sugiura N, Wada K, Kita K, Hirooka N, et al. Histological features and clinical course of large regenerative nodules: evaluation of their precancerous potentiality. HEPATOLOGY 1990; 12: 592598.
  • 18
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421430.
  • 19
    Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27: 201205.
  • 20
    Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457481.
  • 21
    Cox DR. Regression models and life table. J R Stat Soc 1972; 34: 187220.
  • 22
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463472.
  • 23
    Benvegnù L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, et a. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 24422448.
  • 24
    Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004; 99: 636644.
    Direct Link:
  • 25
    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105114.
  • 26
    Bruno S, Borzio M, Battezzati PM. Interferon-alpha in chronic hepatitis C. Ann Intern Med 1998; 128: 956.
  • 27
    Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients whit cirrhosis: a case-control study. Ann Intern Med 1992; 116: 97102.
  • 28
    Gerotto M, Dal Pero F, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006; 44: 8387.
  • 29
    Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 12081236.
  • 30
    Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744749.
  • 31
    Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. HEPATOLOGY 2006; 43: 13031310.
  • 32
    Ichikawa T, Nakao K, Nakata K, Yamashita M, Hamasaki K, Shigeno M, et al. Involvement of IL-1 beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells. Biochem Biophys Res Commun 2002; 294: 414422.
  • 33
    Nakaji M, Yano Y, Ninomiya T, Seo Y, Hamano K, Yoon S, et al. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 2004; 25: 389397.
  • 34
    Merle P, Barraud L, Lefrancois L, Chevallier M, Guerret S, Maisonnas M, et al. Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice. Oncogene 2003; 22: 276271.
  • 35
    Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131136.
  • 36
    Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, et al: Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. HEPATOLOGY 1999; 29: 18701875.
  • 37
    Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225230.